Nicholas Piramal India: Survival Strategies for International Patent Law Regime
|
Code : COM0034
|
Region : USA India
|
||||
 |
 |
 |
 |
||
|
Introduction:Nicholas Piramal IndiaLtd. (NPIL) , one of the leaders in the Indian pharmaceutical industry, had expertise in bulk drug manufacturing (both for domestic and exportmarkets), specialty labs and chemicals, formulation development, providing genomic information and herbal products. NPIL was also a competitive player in contract manufacturing and excelled in (both on- and off-) patent APIs in the regulated markets of the US, Europe and Japan. The key export markets for NPIL were the US, Europe, Asia, including Japan and South East Asia, the Middle East, Africa and Latin America. NPIL's revenue for 2003 was INR 10,575.3 million (INR8,749.92 million in 2002) and earningswere INR1,181.1 million (INR 482.3million in 2002). Over the years, NPIL had engaged in a multi-pronged strategy of acquisitions, brand building, focused selling and manufacturing, expansion of R&D and new recruitment policy for core functions. The company had implemented these strategies as it had realised the implications of the International Patent Law(IPL) proposed to be implemented from January 1st 2005. |
|
| For Case Books
Click Here >> For Case eBooks Click Here >> |
|
